Substituted benz-azoles and methods of their use as inhibitors of Raf kinase

US7728010B2 · kind B2 · utility

Assignee

• Novartis Vaccines and Diagnostics, Inc. · US

Inventors

• Payman Amiri · Emeryville, US
• Wendy J. Fantl · Emeryville, US
• Teresa Hansen · Danville, US
• Barry Haskell Levine · Lafayette, US
• Christopher McBride · Oakland, US
• Daniel Poon · Piedmont, US
• Savithri Ramurthy · Walnut Creek, US
• Paul A. Renhowe · Danville, US
• Cynthia Shafer · El Sobrante, US
• Sharadha Subramanian · San Ramon, US
• Leonard Sung · San Mateo, US

Key dates

• Filing date: Nov 18, 2005
• Grant date: Jun 1, 2010
• Expiry date: Jun 22, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D453/02
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.